Summary

• SPRAVATO is not indicated for the treatment of multiple sclerosis.
• Clinical studies designed to evaluate the efficacy and/or safety of SPRAVATO in patients with multiple sclerosis have not been performed.
• Comorbid multiple sclerosis was not an exclusion criterion in the SPRAVATO clinical trial programs.

LITERATURE SEARCH

A literature search of MEDLINE®, EMBASE®, BIOSIS Previews®, DERWENT® (and/or other resources, including internal/external databases) conducted on 26 February 2025 did not identify any relevant citations pertaining to this topic.